Patent
Methods and compositions for the treatment of cancer and related hyperproliferative disorders
| العنوان: | Methods and compositions for the treatment of cancer and related hyperproliferative disorders |
|---|---|
| Patent Number: | 9,187,485 |
| تاريخ النشر: | November 17, 2015 |
| Appl. No: | 14/052074 |
| Application Filed: | October 11, 2013 |
| مستخلص: | The present invention relates to methods of treating a disease related to cell hyper-proliferation via administration of a therapeutically effective amount of a compound having a general tripartite structure A-B-C. In the tripartite structure A, B, and C are identical or non-identical structures, for example, but not limited to, heterocyclic, phenyl or benzyl ring structures with or without substitutions and are described in detail herein. The methods may utilize particular compounds, for example, having a piperidinyl, a pyrrolinyl or pyridinyl A ring, a thiazole B ring, and a phenyl C ring which may be further substituted independently. |
| Inventors: | Uesugi, Motonari (Osaka, JP); Wakil, Salih J. (Houston, TX, US); Abu-Elheiga, Lutfi (Houston, TX, US); Watanabe, Mizuki (Kyoto, JP) |
| Assignees: | Baylor College of Medicine (Houston, TX, US) |
| Claim: | 1. A method for treating breast cancer or prostate cancer in a patient in need thereof, comprising the step of administering to the patient, in a pharmaceutically acceptable medium, a therapeutically effective amount of a compound having the chemical structure: [chemical expression included] wherein R is H, isopropyl, benzyl, cyclohexyl, cyclopropylmethyl, —COMe, tert-butyloxycarbonyl, or methylsulfonyl, or a pharmaceutically acceptable salt or a stereoisomer thereof or a combination thereof. |
| Claim: | 2. The method of claim 1 , wherein the chemical structure is: [chemical expression included] |
| Claim: | 3. A method for treating breast cancer or prostate cancer in a patient in need thereof, comprising the step of administering to the patient, in a pharmaceutically acceptable medium, a therapeutically effective amount of a compound that is: 4-(4-bromophenyl)-2-(1-propylpyrrolidin-2-yl)thiazole, N-(4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl)methanesulfonamide, 4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)benzenamine, N-isopropyl-4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)benzenamine, N-(4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl)acetamide, N-(cyclopropylmethyl)-4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)benzenamine, N-benzyl-4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)benzenamine, N-cyclohexyl-4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)benzenamine, 4-(3-(pyridin-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-N-tosylbenzenamine, (Z)-4-(3-cyano-3-(4-(2,4-dimethylphenyl)thiazol-2-yl)allyl)-N-(thiazol-2-yl)benzenesulfonamide, N-(4-(6-methylbenzo[d]thiazol-2-yl)phenyl)-2-(N-m-tolylmethylsulfonamido) acetamide, or N-(4-(6-methylbenzo[d]thiazol-2-yl)phenyl)-2-(N-p-tolylmethylsulfonamido) acetamide. |
| Patent References Cited: | 4791200 December 1988 Press et al. 5643932 July 1997 Chihiro et al. 7151196 December 2006 Wilkening et al. 7153889 December 2006 Altenbach et al. 8927578 January 2015 Uesugi et al. 2006/0229363 October 2006 Hamanaka 2014/0038984 February 2014 Uesugi et al. 0513387 November 1992 1092711 April 2001 1348706 October 2003 11186479 June 1999 9814191 April 1998 0106261 January 2001 02068417 September 2002 2006017384 February 2006 2006080406 August 2006 2007001973 January 2007 2013110007 July 2013 |
| Other References: | STN—14052074A—Preliminary—Oct. 11, 2014. cited by examiner Choi et al., Journal of Biological Chemistry, (2003), 278(9), p. 7320-24. cited by examiner Bilgin, et al. 2-Pyridylthiazoles II synthesis and structure elucidations, Acta Pharmaceutical Turcica, 1999;vol. 30:133-137. cited by applicant Choi, et al. Identification of bioactive molecules by adipogenesis profiling of organic compounds, J Biol Chem, Feb. 28, 2003;vol. 278(9);7320-7324. cited by applicant Ide, et al. Sesamin, a sesame lignin, decreases fatty acid synthesis in rat liver accompanying the down-regulation of sterol regulatory element binding protein-1, Biochemica et Biophysica Acta, 2001;1534:1-13. cited by applicant Kamisuki, et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP, Chemistry & Biology, 2009;16:882-892. cited by applicant Kamisuki, et al. Synthesis and elevation of diarylthiazole derivatives that inhibit activation of sterol regulatory element-binding proteins, J Med Chem, 2011;54(13):4923-4927. cited by applicant Sanfillippo, et al. Synthesis of (aryloxy)alkylamines. 1. Novel antisecretory agents with H+K+-ATPase inhibitory activity, J Med Chem, 1988;31:1778-1785. cited by applicant Vachal, et al. Highly selective and potent agonists of sphingosine-1-phosphate 1 (S1P1) receptor, Bioorg Medchem Lett, 2006;16:3684-3687. cited by applicant Reilly, et al. Proceedings of the Nutritioin Society 2003;vol. 62, pp. 611-619. cited by applicant Pinent, et al. Int J Obesity, 2005;29:934-941. cited by applicant Das, et al. A rapid and high-yielding synthesis of thiazoles and aminothiazoles using ammonium-12-molybdophosphate, J Mol Catal A, Jun. 2006;252:235-237. cited by applicant Uesugi, M Organic compounds that control SREBP activities, Ikagaku Oyo Kenkyu Zaidan Kenkyu Hokoku, 2006;25:168-172. cited by applicant Chihiro, et al. Novel thiazole derivatives as inhibitors of superoxide production by human neutrophils: synthesis and structure-activity relationships, J Med Chem 1995;38:353-358. cited by applicant |
| Primary Examiner: | Chu, Yong |
| Attorney, Agent or Firm: | Adler, Benjamin Aaron |
| رقم الانضمام: | edspgr.09187485 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |